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Integrin avb6 is an important emerging target for both imaging and therapy of cancer that requires
specific ligands based on Arg-Gly-Asp (RGD) peptides. There remains little correlation between
integrin-RGD ligand specificity despite studies suggesting an RGD-turn-helix ligand motif is
required. Here, we describe the application of 15N NMR relaxation analyses and structure
determination of avb6 peptide ligands in the presence and absence of trifluoroethanol (TFE) to
identify their critical molecular nature that influences specificity, interaction and function. Two linear
peptides; one known to demonstrate avb6 specificity (FMDV2) and the other based on a natural
RGD ligand (LAP2), were compared to two additional peptides based on FMDV2 but cyclised in
different positions using a disulphide bond (DBD1 and DBD2). The cyclic adaptation in DBD1
produces a significant alteration in backbone dynamic properties when compared to FMDV2; a
potential driver for the loss in avb6 specificity by DBD1. The importance of ligand dynamics are
highlighted through a comprehensive reduced spectral density and ModelFree analysis of peptide 15N
NMR relaxation data and suggest avb6 specificity requires the formation of a structurally rigid helix
preceded by a RGD motif exhibiting slow internal motion. Additional observations include the effect
of TFE/water viscosity on global NMR dynamics and the advantages of using spectral density NMR
relaxation data to estimate correlation times and motional time regimes for peptides in solution.
Introduction
Integrins are heterodimeric glycoproteins composed of non-
covalently linked a and b subunits1 that dynamically translate
extracellular matrix cues into intracellular responses, including
mechanical, biochemical, and genetic signals, thereby modulat-
ing cell proliferation, survival, migration, and invasion.2 These
properties make many integrins key determinants of the survival
and spread of cancer and one such integrin, avb6, is only
expressed on epithelia and then only during processes of tissue
remodelling; including wound healing, chronic inflammation,
and cancer.3,4 Many investigations have identified avb6 as
imparting a pro-invasive and aggressive phenotype when over-
expressed on cancer cells4–7 that reflects the clinical situation in
humans, since survival from cancer of the colon, cervix or from
non-small cell lung cancer is reduced significantly if cancers
express high levels of avb6.8 Integrin avb6 is scarce or absent in
normal tissue but its presence drives tumour invasion and
shortens survival, therefore it represents a major new specific
molecular target for many cancers. There are 24 known integrins
that cover a variety of signalling functions1 and it is imperative
that specific molecular targeting to avb6 is achieved to maximise
opportunities for tumour imaging and therapy. The challenge for
specific molecular recognition of ligands toward avb6 is
complicated by it being a member of the arginine-glycine-
aspartic acid (RGD) receptor class of integrins that includes
avb3, avb5, avb8, a8b1, a5b1 and aIIbb3.
Peptide agonists with increased specificity to avb6 have been
found to recognise an extended motif Asp-Leu-Xxx-Xxx-Leu
(DLXXL)9 creating a larger recognition sequence of
RGDLXXL. We have previously reported that 20-mer peptide
ligands in 30% (v/v) trifluoroethanol (TFE) form structures with
RGDLXXL turn-helices where increased helix length correlated
with affinity toward avb6.10 TFE promotes secondary structure
in peptides11 and influences protein structure and function12
therefore the relevance of the TFE induced helix to avb6 binding
requires confirmation. 1H STD NMR10 and 13C, 1H 2D STD
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NMR,13 has established avb6 peptide ligands bind in a helical
conformation that mirrors the TFE induced structure; justifying
the approach of analysing the structures of these peptides using
TFE/buffer solutions. The highest specificity peptide toward
avb6 to date is A20-FMDV2, with the primary sequence
NAVPNLRGDLQVLAQKVART. This peptide sequence was
taken from the surface GH loop motif from foot and mouth
disease virus serotype O1 BFS capsid protein VP114 and is a
known ligand for integrin avb6.10 The FMDV GH loop sequence
is very divergent, however the primary recognition motif RGD
and to an extent the longer motif RGDLXXL is highly
conserved among field isolates.15 A20-FMDV2 has been shown
to exhibit extremely high specificity toward avb6 over other
integrins from in vitro10 and in vivo studies, the latter using
mouse models that illustrate clear selectivity of A20-FMDV2 for
avb6 over avb3; thus proving the potential of avb6 as a cancer
target.8,16
A20-FMDV2 exhibits great promise but, there are advantages
to providing either mimetics or modified versions of this peptide
to enhance affinity, increase in vivo half-life and reduced
clearance for maximum avidity in clinical use. One such method
to improve stability is to cyclise the peptide. Cyclised versions of
A20-FMDV2 were produced using a disulphide bond but despite
an increase in serum stability, this peptide produced little if any
increase in avb6 affinity and a decrease in avb6 specificity. This
surprising observation suggests avb6 is sensitive to subtle ligand
properties and we report in this 15N NMR dynamics study that
ligand conformational rigidity correlates with avb6 ligand
specificity.
Isotopic enrichment provides relatively straightforward access
to backbone dynamics over the nanosecond to picosecond
timescale as well as affording much-improved precision in the
structural elucidation process. NMR backbone dynamics report
on the overall tumbling behaviour of the peptide in solution,
defined by the molecular correlation time tm, as well as dynamic
internal detail via order parameters S2 and internal motion
correlation times te reporting on each
15NH bond vector across
the peptide backbone. The order parameter can also be devolved
into two separate order parameter processes; Sf
2 for fast motions
and Ss
2 for slow motions where all order parameters are
permitted to take values between 0.0 and 1.0; these extremes
defining a fully disordered random or rigid ordered system
respectively. Another important role of NMR relaxation data is
to identify and isolate conformational exchange events through
the parameter Rex. NMR solution dynamics have been useful
tools in the study of protein internal and global motions related
to function but has found very limited use in peptides to date
with few examples existing beyond the utility of natural
abundance 13C NMR relaxation to study nascent structure,17,18
observing flexibility differences between oxidised and reduced
peptide forms19 or in membrane peptide analysis.20,21 Our study
is the first to observe dynamic changes in the presence and
absence of TFE using 15N NMR peptide relaxation with
combined ModelFree and spectral density methods that verify
this approach for peptides within TFE-buffer systems. Four





All peptides contain a C-terminal modification of a methio-
nine to a homoserine lactone (Hsl) that occurs from cyanogen
bromide cleavage of the recombinant peptide from its fusion
partner; hence the removal of ‘A20’ in peptide names used in
previous studies; FMDV2 is A20-FMDV2-Hsl and provides a
benchmark for a peptide with high avb6 affinity. DBD1 and
DBD2 are modified FMDV2 peptides, each with a different
intramolecular disulphide bond linkage that was designed to
support the original A20-FMDV2 structure.10 The disulphide
bond serves two purposes; (a) to force stabilisation of the turn-
helix topology and (b) to provide in vivo serum stability for
clinical use; cyclising peptides has been a successful approach to
stabilise peptides in the radiopharmaceutical field for many
years. Additional residues Glu1-Lys2 in DBD1 and Tyr2 in
DBD2 were inserted to enable in vivo imaging labels to be easily
attached to the peptides. LAP2 is a natural avb6 ligand based
upon the latency associated peptide (LAP) of a transforming
growth factor (TGFb1) with a single mutation M16L to allow
cleavage of the peptide from the recombinant fusion partner by
cyanogen bromide.22,23 Unlike FMDV2, LAP and LAP2 have
high affinities for integrins other than avb6 and provide
comparison data with respect to this wider spectrum of targets.
This NMR based structural and dynamic study of these four
21-mer avb6 peptide ligands illustrates that differences in peptide
design, through disulphide bond cyclisation, dramatically alters
the fundamental properties of the ligand that in turn influence
their affinity and specificity toward avb6. Our study informs on
the critical molecular nature of integrin ligands that defines their
interaction and function; optimal ligands for avb6 can be
designed in the future. These results also illustrate that the
design of drugs or agents toward integrins requires careful
consideration of structure and dynamic ligand properties.
Results
Peptide production and purification
Production and purification of all peptides was completed with
comparable yields by following our published protocol23 with
one exception: post-translation formylation was observed with
LAP2 peptide that was subsequently circumvented by solubilis-
ing the peptide for CNBr cleavage in trifluoroacetic acid.
Peptide NMR assignments and structural elucidation
All peptides were assigned in the presence and absence of TFE
and the structures of the peptides in the presence of TFE solved
using 2D and 3D 15N edited NOESY datasets. Assigned 15N–1H
HSQC datasets for each peptide and all peptide NMR assign-
ments are available (Fig. S1 and Table S1, ESI{). The structure
closest to the mean for each peptide is shown in Fig. 1 and
structural ensembles and statistics shown in Fig. S2 and Table S2
in ESI{. All ensembles show variation due to low numbers of
structural restraints beyond the helical regions but disorder is
better identified using NMR relaxation dynamics. Structural
limits for each peptide are also defined in Fig. 1 that includes a
schematic of contacts and restraints. Fig. 1 confirms all peptides
conform to the RGD-turn helix motif as reported previously10
and additional structural information is reported in the ESI{.
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15N NMR relaxation studies ± TFE
Relaxation parameters were obtained for individual amino acids
in each peptide in the absence of TFE (Fig. S3, ESI{) and mean
values for each parameter within its respective peptide are
summarised in Table 1(a). In the absence of TFE, relaxation
parameter sets distinguish disulphide bonded cyclic peptides
from free peptides. FMDV2 and LAP2 free peptides exhibit
variability across T1 (longitudinal relaxation time), T2 (trans-
verse relaxation time) and g (heteronuclear NOE) that defines
both termini from larger T1 and T2 values and highly negative g
values. DBD1 and DBD2 values are significantly different and
confirm a compact topology is present for these peptides even in
the absence of TFE. The global correlation time tm, in the
absence of TFE, was estimated for DBD1, DBD2, FMDV2 and
LAP2 to be 2.4 ¡ 0.1, 3.8 ¡ 0.4, 1.4 ¡ 0.4 and 3.3 ¡ 0.2 ns
using dipolar T1 and T2 equations to correlate average observed
to theoretical T1/T2 ratios for each peptide. Despite using S
2 =
0.2 in the theoretical treatment (to account for unstructured
random coil), these results confirm that T1/T2 ratios place
emphasis on the spin–spin relaxation time (T2) for the estimation
of tm. As peptides provide a small population of relaxation data,
estimated tm values need additional supporting validation if
subsequent ModelFree analysis is required.
Relaxation parameters were obtained for individual amino
acids in each peptide in the presence of TFE (Fig. S4, ESI{) and
mean values for each parameter within its respective peptide are
summarised in Table 1(b). FMDV2 and LAP2 illustrate a
reduction of both T2 and g across the structurally defined helical
regions for each peptide to confirm the formation of a rigid
secondary structure element in the presence of TFE validating
the structural limits as outlined in Fig. 1. Relaxation data of
DBD1 and DBD2 support TFE promoting helix formation
despite these peptides being constrained through the disulphide
bond. Using an average S2 of 0.86 representing a structured
state, the global correlation time tm for DBD1, DBD2, FMDV2
and LAP2 were estimated to be 6.6 ¡ 0.7, 4.9 ¡ 0.1, 4.9 ¡ 0.2
and 3.7 ¡ 0.1 ns respectively in the presence of TFE; also
exhibiting variation influenced by T2 when using T1/T2 ratio
estimates. This is most noticeable with DBD1 where the average
15N T2 in TFE is depressed compared to other peptides and
suggests exchange line broadening is present in the data.
Discounting DBD1, all estimations of tm in TFE are approxi-
mately double that expected based on back extrapolation of
protein data using residue number24 that predicts 21 residue
structures at 10 uC to have a tm of 2.8 ns. The 30%(v/v) TFE/
buffer mixture is reported to have double the viscosity of water
at 10 uC25 which explains this increase in correlation time. This
also rationalizes the practical advantage of using NOE over
ROE for TFE based peptide structure determination. Equally,
knowledge of this viscosity effect further supports our use of low
levels of TFE to complete the co-operative transition of helix
formation as devised from previous far-UV CD observations.10
These relaxation data must be considered in context with
advanced analysis methods below.
Reduced spectral density mapping
15N relaxation parameters report on the motional properties of
each peptide and such motions are translated through spectral
density functions that, being defined from the autocorrelation
function, describe the limit and amplitude of frequencies of
motions experienced from the reorientations of 15N–1H bond
vectors in each peptide. 15N relaxation parameters (Fig. S3 and
S4, ESI{) were used to determine reduced spectral density values
that makes no assumptions on timescales of motion in the
Fig. 1 Structures closest to the mean for each peptide and NOE
contacts, hydrogen bond restraints assigned for DBD1(a), DBD2 (b),
FMDV2 (c) and LAP (d) in the presence of 30% (v/v) TFE. Key residues
of the RGDLXXL/I motif are shown as sticks on each structure.
Table 1 Average 15N relaxation parameters for DBD1, DBD2,
FMDV2 and LAP2 peptides obtained at 14.1 T (600 MHz 1H) and 10 uC
(a) No TFE
15N T1 (ms)
15N T2 (ms) g
DBD1 558 ¡ 5 394 ¡ 5 20.70
DBD2 551 ¡ 5 298 ¡ 5 20.71
FMDV2 696 ¡ 5 592 ¡ 5 21.20
LAP2 768 ¡ 5 461 ¡ 5 21.20
(b) 30% (v/v) TFE
15N T1 (ms)
15N T2 (ms) g
DBD1 582 ¡ 31 114 ¡ 12 20.54
DBD2 523 ¡ 6 157 ¡ 3 20.40
FMDV2 572 ¡ 15 169 ¡ 6 20.27
LAP2 768 ¡ 6 229 ¡ 5 20.59
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molecule under investigation; a clear advantage with small
datasets. Spectral densities were estimated at three frequencies:
zero, vN and 0.87vH where we have adopted the notation that
describes each spectral density as J(0), J(vN) and J(vh).
26
Timescales of motion of the 15N–1H bond vector are expressed
by each spectral density estimate where J(0) describes milli-
second to nanosecond motion, J(vN) nanosecond motion and
J(vh) nanosecond to picosecond motion that are qualitatively
described as slow, intermediate and fast time regimes respec-
tively. Plots of spectral densities with residue number for each
peptide in the absence and presence of TFE are available (Fig.
S5, ESI{). Spectral density values can be interrogated graphically
in order to appreciate the motional time regimes within proteins
under investigation27–29 and Fig. 2 and Fig. 3 illustrate this
approach for peptide data in the absence and presence of TFE.
The solid curved lines in each figure are an aid to interpretation
and represent the simple Lorentzian model of spectral density
calculated for a range of correlation times; equivalent to an order
parameter S2 = 1.0 for an isotropic system. Specific motional
time points for these curves are shown in Fig. S6, ESI{. The
scatter of data within each curve is due to global and local
motion that can be explained using ModelFree order parameters
S2, Sf
2 and Ss
2 as well as exchange line broadening contributions,
Rex. Linear curve fitting of the data defines line segments that
intercept the solid Lorentzian line at specific time points to
provide estimates of the timescales of motion for each peptide in
the absence and presence of TFE. Data was further utilised to
Fig. 2 Parametric curves showing the dependence of J(vN) on J(vh) for
individual 15N nuclei from (a) DBD1-TFE, (b) DBD2-TFE, (c) FMDV2-
TFE, (d) LAP2-TFE, (e) DBD1+TFE, (f) DBD2+TFE, (g)
FMDV2+TFE and (h) LAP2+TFE. Defined structure regions from
Fig. 1 are coloured blue for RGD-turn and red for the helix region for
each peptide. The continuous curved line represents the dependence of
theoretical Lorentzian spectral density functions with variable correla-
tion time. The large-dashed line (– – – –) is a least-squared fit to all the
data points in (a–h), the small-large-dashed line (- – - –) is a fit to only
RGD-helix data points in (a–d) and the small-dashed line (- - - -) is the
motional extremes as defined from the data. Motional times defined as
the intercept of each dashed line with the theoretical curve are shown on
individual plots.
Fig. 3 Parametric curves showing the dependence of J(vh) on J(0) for
individual 15N nuclei from (a) DBD1-TFE, (b) DBD2-TFE, (c) FMDV2-
TFE, (d) LAP2-TFE, (e) DBD1+TFE, (f) DBD2+TFE, (g)
FMDV2+TFE and (h) LAP2+TFE. Defined structure regions from
Fig. 1 are coloured blue for RGD-turn and red for the helix region for
each peptide. The continuous curved line represents the dependence of
theoretical Lorentzian spectral density functions with variable correla-
tion time. The large-dashed line (– – – –) represents a least-squared fit to
all the data points in (a–h). Motional times defined as the intercept of
each dashed line with the theoretical curve are shown on individual plots.
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understand specific motional behaviour of both RGD-turn (blue
data points) and helix motifs (red data points) as defined from
the structural data.
Fig. 2 (a–d) displays J(vh) vs. J(vN) plots for each peptide in
the absence of TFE. DBD1 (Fig. 2a) and DBD2 (Fig. 2b) can be
analysed using a single fitted dashed line with virtually all
15N–1H bond vectors across the peptides clustering regardless of
position in the sequence or presence in the RGD-turn or helix
motif. Intercept points for both DBD1 and DBD2 provide
similar estimates of the motional times t of 1.9 ns/75 ps and
1.8 ns/75 ps (global/local motion); supporting both disulphide
bonded peptides tumbling in concert over the entire sequence. In
contrast, non-cyclic peptides FMDV2 (Fig. 2c) and LAP2
(Fig. 2d) display a larger distribution of their spectral density
data in the absence of TFE and linear line fitting is different
when applied to the entire dataset or to data from the RGD-helix
motif. For FMDV2, motional times t of 2.7 ns/100 ps (all values)
and 3.9 ns/125 ps (RGD-helix) are obtained with LAP2
providing 2.6 ns/95 ps (all values) and 3.8 ns/120 ps (RGD-
helix). As with DBD1 and DBD2, data is comparable between
FMDV2 and LAP2 for all residues suggesting similar motional
properties but increases in t for the RGD-helix support the
presence of nascent structure and short-term structural order.
The position of data on each fitted line is influenced by its
effective order parameter S2 that can be quantitatively deter-
mined as shown in the original manuscript.27 However, it is
sufficient here to notice FMDV2 and LAP2 data is distributed to
the left of the fitted line and closer to the J(vN) axis supporting
overall S2 values for FMDV2 and LAP2 as lower than those for
DBD1 and DBD2 in the absence of TFE. Equally, RGD and
helix motif data for FMDV2 and LAP2 occurs further from the
J(vN) axis and supports an increased order parameter S
2
compared to data outside these motif regions. This is under-
pinned by the larger motional time values obtained for these
motif regions and we conclude that this method of data handling
is useful for discerning structural propensity and relative order in
poorly defined regions. Furthermore, these estimates of t proved
useful for ModelFree analysis shown below.
Fig. 2(e–h) displays J(vh) vs. J(vN) plots for each peptide in
the presence of TFE with data average fitted dashed lines that
define overall and RGD-helix motional limits converging to a
point of common overall correlation time. Fig. 2(e) and 2(f)
show the cyclic peptides DBD1 and DBD2 continue to exhibit
similar J(vh) and J(vN) in the presence of TFE with average
motional times, t, estimated to be 5.9 ns/180 ps and 5.8 ns/185 ps
respectively; even the overall limits estimated from the curves are
comparable at 70 ps/800 ps and 75 ps/750 ps respectively. Despite
significant differences in structure, the overall dynamic nature of
DBD1 and DBD2 are similar on both J(vh) and J(vN) time
scales and such comparable motional properties must be driven
primarily by the cyclic nature rather than defined structural
regions. Differences are apparent upon comparison of RGD and
helix regions with DBD2+TFE helix data being closer to the
intercept point and so having higher order parameter S2 values
than the RGD-turn. In contrast, DBD1+TFE provides a diffuse
data pattern with the helix data specifically not forming a
compact arrangement close to the intercept. This is, in part, due
to DBD1+TFE data being unique and the only dataset to be
described by a single order parameter S2 together with a internal
correlation time te. However, residual broadening was also
observed in Fig. 3(e). In contrast, non-cyclic peptides demon-
strate more diverse J(vh) and J(vN) defined motional properties
that are reflective of the different structural regions promoted by
the co-solvent. Fig. 2(g) and 2(h) provide average motional times
for FMDV2+TFE and LAP2+TFE of 7.5 ns/220 ps and 6.0 ns/
350 ps respectively and motional limits of 60 ps/1 ns and 100 ps/
850 ps. Motional values are similar but FMDV2 has a global
correlation time 1.5 ns slower in addition to a lower average
internal correlation time but with broader limits. The most
important observation is the compact nature of FMDV2 helix
data points (Fig. 2(g)) supporting order parameter S2 values
approaching 1.0 for these NH vectors. The RGD-turn region
data are distributed just beyond the helix and unstructured
terminal residues define the extreme limits in Fig. 2(g).
LAP2+TFE data has a broad distribution along the linear
average line suggesting less order overall than that observed for
FMDV2. Again, these estimates of correlation time and
motional time regimes proved useful for ModelFree analysis.
Fig. 3(a–h) demonstrate the use of J(vN) vs. J(0) for all
peptides in the absence or presence of TFE to evaluate data for
chemical exchange contributions that manifest as line broad-
ening and generate larger values of J(0). This is clearly
demonstrated in Fig. 3(e) for DBD1+TFE where helix data fall
outside the theoretical Lorentzian line. These data can also be
interrogated via a linear line that acts as a barometer for the
order parameter S2 and the dotted-Lorentzian line intercept
signifies S2 is zero on the left intercept and is 1.0 on the right
intercept. Fig. 3(a–d) illustrate the difficulty in producing linear
fits for data in the absence of TFE due to the narrow range of
J(0) obtained, that in turn was expected from systems tumbling
with low correlation times and low effective order parameters. In
contrast, Fig. 3(e–h), for peptides in the presence of TFE,
provided correlation time estimates more comparable to those
obtained from Fig. 2(e–h). The value of 7.9 ns for DBD1+TFE is
2.0 ns longer than that derived from Fig. 3(e) but the NH vectors
in the helix of this peptide are clearly in chemical exchange.
Fig. 3(f–h) provide correlation time estimates for DBD2+TFE,
FMDV2+TFE and LAP2+TFE of 6.3 ns, 6.9 ns and 6.1 ns
which compare favourably with Fig. 2(f–h) estimates of 5.8 ns,
7.5 ns and 6.0 ns.
Lipari-Szabo ModelFree analysis of NMR relaxation parameters
Fig. 4 displays the ModelFree parameters obtained for all
peptides in the presence of TFE where each appropriate model
was identified using a common selection strategy30 together with
global correlation time data obtained from extended spectral
density analysis. This approach provided lower chi-squared
fitting values than using correlation times obtained directly from
NMR relaxation parameters. The overall order parameter S2 for
each peptide supports increased order across the entirety of both
disulphide bonded cyclic peptides unlike FMDV2 and LAP2
where S2 values ,0.5 are observed at the termini.
DBD1+TFE relaxation data was unique in being the only
dataset to be described using a single order parameter S2
together with the correlation time for internal motion te.
However, residues Cys3, Asn5, Val12, Ala14, Gln15, Val17,
Cys18, Arg19 and Thr20 all required contributions to account
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for additional line broadening due to chemical exchange,
characterised by Rex as identified in Fig. 4(i); confirming the
validity of data points to the right of Lorentzian boundary in
Fig. 3(e). The unique nature of DBD1+TFE data is also seen
with concomitant te contributions ,500 ps (with the exception
of Thr20) that are smaller than those within the remaining
peptides. This is most apparent for the RGD region that displays
an average te across the three amino acids of ca. 0.15 ns
compared to 0.96 ns, 1.60 ns and 1.15 ns for DBD2+TFE,
FMDV2+TFE and LAP2+TFE respectively. Rex and te con-
tributions label DBD1+TFE as having unique properties among
the peptides studied.
Helical regions of DBD2+TFE, FMDV2+TFE and
LAP2+TFE provided optimal ModelFree chi-squared values
when using a single order parameter and internal correlation
time. However, data for most residues outside the helical region
did not provide satisfactory fits from a S2/te model and optimal
fits were obtained using two internal motion processes covering
fast and slow nanosecond timescale events, as described by their
own specific order parameters Sf
2 and Ss
2. Sufficient data
redundancy was maintained by estimating only te in addition to
Sf
2 and Ss
2 and in these cases Sf
2?Ss
2 = S2. Unlike DBD1+TFE,
DBD2+TFE exhibits slow and fast motion contributions
although S2 values remain greater than 0.7 across the peptide
with the exception of Cys20 and Hsl21 (Fig. 4b); suggesting a
reasonably rigid backbone as expected. These differences
compared to DBD1+TFE are most likely due to the open
structural arrangement of DBD2+TFE (Fig. 1b). The RGD
region of DBD2+TFE displays internal motion of 0.04/2.00/0.85
ns for Arg7/Gly8/Asp9 and is slower compared to DBD1+TFE
Fig. 4 Column plots describing the results of model-free Lipari-Szabo analysis of (a), (e) and (i) DBD1+TFE, (b), (f), (j) and (m) DBD2+TFE, (c), (g),
(k) and (n) FMDV2+TFE and (d), (h), (l) and (o) LAP2+TFE with amino acid sequence. Data reporting within TFE defined structure regions from
Fig. 1 are coloured blue for RGD-turn and red for the helix region for each peptide.
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(Fig. 4e) but not as slow as observed for Arg7/Gly8 of
FMDV2+TFE (see below).
ModelFree data for FMDV2+TFE and LAP2+TFE highlight
different overall S2 order parameter in Fig. 4c and 4d. Helical
regions provide average S2 of 0.83 ¡ 0.04 and 0.76 ¡ 0.07 for
FMDV2+TFE and LAP2+TFE respectively. The helix in
FMDV2+TFE displays the highest overall rigidity of all peptides
studied and despite not having a disulphide-bond to hold the
peptide in a cyclic conformation, FMDV2+TFE has average
termini S2 values of 0.54 ¡ 0.11 compared to 0.28 ¡ 0.14 for
LAP2+TFE suggesting increased rigidity in the termini of
FMDV2+TFE. Fig. 5g and 5h highlight significant slow internal
motions in both termini of LAP2+TFE that manifest in the
C-terminus of FMDV2+TFE but are not as prevalent within its
N-terminus. This is supported by NOEs observed in
FMDV2+TFE between N-terminal residues and the turn-helix.
In contrast, LAP2+TFE displays mobile termini where Ss
2 , Sf
2
that dominates as the low overall order parameters in Fig. 5d.
The RGD region of FMDV2+TFE suggests Asp9 has similar
dynamic characteristics as the helix with Ss
2 = 0.95 but Arg7 and
Gly8 have significant slow internal motion values of 2.38 ns and
2.48 ns respectively. In contrast, the internal correlation times of
Arg7/Gly8 of LAP2+TFE are more comparable to Gly8 in
DBD2+TFE. FMDV2+TFE has the most ordered helical region
and termini of the non-cyclic peptide pair but also exhibits
comparatively slow internal motions in the Arg-Gly region of the
RGD motif when compared to the other peptides. LAP2+TFE
exhibits very flexible termini making this peptide unique.
A ModelFree investigation of relaxation data in the absence of
TFE using correlation times derived from Fig. 2(a–d) is shown in
Fig. 5. Data fits support both cyclic peptides having rigidity
across their respective sequences, as suggested above. Order
parameter S2 remains fairly constant across the RGD-helix
regions of both DBD1-TFE and DBD2-TFE; supporting the
disulphide bonds promoting interaction between the N- and
C-terminal regions of each peptide. In contrast both FMDV2-
TFE and LAP2-TFE provide similar S2 profiles that would be
expected from peptides with no defined structure in solution
although increased order parameter toward the centre of the
peptide acknowledges a reduction in the backbone degrees of
freedom. Close inspection of Fig. 5c and 5d indicate that the
helix forming regions have increased order, as illustrated in
Fig. 5c where Val17 has an S2 of 0.45 but the equivalent residue 5
amino acids from the N-terminus, Asn4, has an S2 value of 0.35.
This provides evidence for the S2 maximum is at Leu13 in
FMDV2-TFE unlike the sequence centre at Gln11. The
asymmetry observed in the order parameter of FMDV2 in the
absence of TFE suggests the presence of nascent structure in this
peptide; these subtle but significant changes are supported by the
spectral density data in Fig. 2c and 2d; this verifies the use of
NMR relaxation parameters in the study nascent structure. The
equivalent asymmetry in the order parameter profile of LAP2-
TFE is less obvious due to the smaller helix placing the largest S2
values in the middle of the peptide.
Implications of peptide structure and NMR relaxation dynamics
for integrin recognition and specificity
Specificity of biotinylated peptides for avb6 was assessed using
the paired cell lines A375P.Beta6.puro and A375P.puro.10 Both
cell lines express integrins avb8, avb5, avb3 and a5b1 (data not
shown) but only A375P.Beta6.puro expresses avb6. Biotinylated
A20FMDV2, DBD1 and DBD2 bind to A375P.Beta6.puro at
nanomolar concentrations but only at micromolar concentra-
tions to A375P.puro (Fig. S7, ESI{), showing a high degree of
both affinity and specificity for avb6. DBD1 shows the highest
degree of binding to the avb6-negative A375P.puro, followed by
DBD2, and finally A20FMDV2, which has an extremely low
level of binding even at 10 mM (Fig. S7, ESI{). A20LAP has
previously been shown to have a much lower affinity for avb610
and in similar experiments also bound to A375P.puro at
micromolar concentrations (data not shown).
Discussion
Our previous structure-function studies of RGD peptides toward
integrin avb6 highlighted a clear correlation between helical
length and affinity toward the integrin.10,13 These investigations
supported the proposition that TFE-generated helical peptide
structures are adopted upon binding the integrin. From a
functional viewpoint, FACS analysis of each peptide confirms
FMDV2 as the most avb6 specific peptide and both flow
cytometry (Fig. S7, ESI{) and solid-phase binding assays (data
not shown) demonstrate that cyclisation via a disulphide bond
does not detrimentally change affinity toward avb6 in DBD1 and
DBD2. However like LAP2, DBD1 and DBD2 also bind to
integrin avb6-negative cells that express integrins avb3, avb5,
avb8 and a5b1; the unique specificity of FMDV2 to integrin
avb6 is lost due to the addition of the disulphide bond even
though DBD1 and DBD2 are sequence related to FMDV2.
Fig. 1 illustrates that each peptide adopts a specific helical
conformation in TFE; a potential basis for both affinity and
specificity differences. Structural differences between DBD1 and
FMDV2 originate from the disulphide bond, as proven by the
Fig. 5 Column plots describing the order parameter S2 results of model-
free Lipari-Szabo analysis of (a) DBD1-TFE, (b) DBD2-TFE, (c)
FMDV2-TFE and (d) LAP2-TFE with amino acid sequence. Data
reporting within TFE defined structure regions from Fig. 1 are coloured
blue for RGD-turn and red for the helix region for each peptide.
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similarities between 15N HSQC data for reduced DBD1 and
FMDV2 (Fig. S8, ESI{). The DBD1 helix is considerably
different in that Leu10 is not within the helical section and this
peptide forms an RGDL-helix motif in contrast to the RGD-
helix motif that DBD2, FMDV2 and LAP2 exhibit. However,
DBD1 displays a higher affinity than FMDV2 for the integrin
although it is not avb6 specific; suggesting the change in
structural motif is not detrimental to avb6 recognition. Our
previous study ranked FMDV2 with higher affinity than LAP
based on helix length10 where length of the helix in TFE followed
as (DBD1 . FMDV2 . DBD2 . LAP2) which correlates with
avb6 affinity (DBD1 . A20FMDV2 ¢ DBD2 . A20LAP).
Affinity to integrins other than avb6 expressed on A375P.puro
cells follows DBD1 . DBD2 . FMDV2, such that specificity to
other integrins does not correlate with helix length.
LAP2+TFE is the most dynamically flexible peptide with
lower S2 values suggesting significant motion at both termini, in
contrast to that observed for FMDV2+TFE. These dynamic
differences clearly separate LAP2 and FMDV2 as distinct from
each other and may account for differences in affinity and
specificity for avb6. Also, slow internal motions observed in the
Arg-Gly of the RGD region of FMDV2 separate it from the
other three peptides studied. These observations suggest
the hypothesis that avb6 specificity is dynamically driven by a
suitable peptide ligand creating a rigid helix with a high order
parameter and an RGD motif with slow internal motions;
properties that FMDV2 demonstrates. It is worth remembering
that LAP2 contains the M16L mutation which could be argued
as sufficiently different to the natural substrate (LAP) to
question these conclusions, but 15N HSQC overlays of LAP
and LAP2 (Fig. S9, ESI{) show the similarity between these two
peptides. 15N-labelled LAP could never be produced in sufficient
quantities for NMR relaxation studies; necessitating the use of
LAP2 instead.
Critical observations involve the role of the disulphide bonds
in both DBD1 and DBD2 that create two peptides with
dramatically different dynamic properties upon helix formation.
The disulphide bond promotes helix formation by destabilising
the unfolded state but it also enforces a reduction in specificity
toward avb6. This makes DBD1 and DBD2 less useful as
starting points for the design of mimetics for cancer therapy or
imaging. DBD2 displays dynamic properties most similar to
FMDV2 and it follows that DBD2’s specificity to avb6 is closest
to FMDV2; an observation that further supports the hypothesis
that ligand dynamics drives avb6 specificity. Equally, the
dynamics of DBD2 are sufficiently diverse from FMDV2 to
differentiate their respective affinities and specificities toward
avb6. This suggests specificity and affinity are finely balanced for
ligands towards avb6 and increased affinity will sacrifice
specificity and vice versa. This concept is supported by the
dynamic and exchange active peptide DBD1 having the highest
affinity toward avb6 at the cost of being a peptide that recognises
other integrins, an observation that equally suggests integrins
other than avb6 interact with conformationally labile ligands.
Ultimately, NMR relaxation dynamics support FMDV2 form-
ing a rigid RGD-helix motif, as shown by the tight compact
nature of data in Fig. 2g, and that this rigid nature supports an
optimal fit to the avb6 ligand-binding site. In addition, this
rigidity is not conducive to binding to other integrins, including
others from the av class and supports the b6 subunit as the key
ingredient for avb6 recognition. As a result, the b-unit must
define specificity across the integrin classes and can sense the
sequence, structure and dynamics of potential ligands.
Conclusions
Isotopically enriched peptides have allowed a precise structure
and dynamic study of ligands with different affinities and
specificities toward integrin avb6. This approach supports our
initial hypothesis that peptide ligand helix formation is linked to
affinity and specificity but has equally identified the dynamic
nature of peptides as important. Our results suggest that integrin
avb6 specific peptides require the formation of a structurally
rigid helix directly following the RGD motif that exhibits slow
internal motion. In combination, specificity and affinity toward
avb6 appear to be dictated by both the dynamic nature and
RGD-turn helix length in the peptide ligand; FMDV2 is
optimised with respect to both properties. As a cautionary
observation, our data also confirms that cyclising peptides can
change their dynamic behaviour in a manner that alters their
affinity and specificity toward avb6. This observation could hold
true for many different protein-target systems investigated in
vitro or within the field of drug screening and discovery.
Finally, from a technological viewpoint, this study has shown
that 15N NMR relaxation for peptides can be achieved using the
same theoretical and practical solution dynamics as used over the
last 20+ years in protein NMR. The combined use of reduced
spectral density and ModelFree formalism has created a unique
insight into ligand dynamic properties that can explain subtle
differences in ligand affinity and specificity for integrin avb6. We
have also confirmed that trifluroethanol-water systems radically
affect the viscosity of solutions that manifest in longer
correlation times for peptides.
Experimental
Plasmid preparation and fusion protein expression and purification
The production and purification of recombinant, isotopically
enriched peptides was completed as previously described23 and is
also reported in detail within the ESI{.
NMR sample preparation
Lyophilised peptide was prepared for NMR analysis to a final
concentration of 1 mM as determined by sample weight. Peptides
were dissolved in NMR buffer of 20 mM Na2HPO4, 100 mM
NaCl, pH 6.5 with 10% (v/v) D2O (Goss scientific Ltd). Samples
had a final volume of 330 mL and transferred to a Shigemi (BMS-
005V) NMR tube for NMR analysis. Peptides analyzed in the
presence of TFE were prepared in 20 mM Na2HPO4, 100 mM
NaCl, pH 6.5 with 30% (v/v) d3-TFE to a final volume of
330 mL. 30%(v/v) TFE was chosen to complement our previous
studies where far-UV circular dichroism confirmed integrin
peptides complete the co-operative transition of helix formation
below this TFE ratio; typically between 15–25% TFE(v/v).10 The
disulphide bonded peptides DBD1 and DBD2 were oxidized in
the presence of a 106 molar excess of oxidised glutathione
before analysis.
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NMR data acquisition, processing and analysis
Standard NMR experiments29 were carried out at 10 uC on a
Varian UnityINOVA with RT-HCN probe and Bruker AV3
spectrometer with QCI-F cryoprobe operating at 14.1 Tesla (1H
resonance frequency of 600 MHz). Specific experiments used for
peptide structure elucidation are described in the ESI{. Each 15N
T1, T2 and heteronuclear NOE experiment was acquired with the
same spectral resolution as HSQC experiments. 10 15N T1
experiments were completed for each peptide and solvent with
differing relaxation delays of 64, 128, 256, 384, 512, 640, 768 and
896 ms with 250 and 640 ms delays repeated. 15N T2 data were
collected with 11 different experiments with relaxation delays of
40, 60, 80, 100, 120, 140, 160, 180 and 200 ms with 80 and 160 ms
delays repeated. Heteronuclear NOE experiments were acquired
with a transient cycle of 5.5 s both with and without saturation
of amide protons. All NMR data were processed using
NMRpipe31 on Linux PCs and all NMR spectra were assigned
and relaxation data analysed using the software package CCPN
Analysis.32
Structure calculation and analysis
NOE distance restraints for each peptide were assigned from 2D
and 3D NOESY datasets with a constant bin size of 1.2 to 5.5 A˚
that is optimal for peptide structures.12 CNS version 1.133 was
used to calculate an initial set of 20 structures for each peptide
with torsion angle/velocity initialized – simulated annealing from
each linear peptide and a total of 10 cycles of energy
minimization were completed, each with 200 cooling steps.
Iterations of visualization and violation analysis were completed
until no van der Waals or NOE violation were seen greater than
0.2 A˚ in line with previous structural studies of integrin
peptides.10 Dihedral angle restraints were applied only to
residues with a-helical conformations as determined by direct
analysis of structures created from NOE restraints. Following
dihedral angle refinement, hydrogen bond donor acceptor pairs
were identified from these intermediate structures and used for
final structural refinement. All restraints were added to a final
calculation of 100 structures, of which the 50 with the lowest
reported energy were further water refined using YASARA
(AMBER96 force field) and became the final ensemble for each
peptide. The precision of each ensemble of 50 structures was
assessed using the program PROCHECK-NMR34 to score
occupation of favourable, allowed or disallowed regions in the
Ramachandran plot. All images of the peptides and ensembles
were made using Pymol.35 Limits of the helix for each peptide
ensemble were defined by a combination of dihedral angles
(confirmed by PROCHECK), NOEs and hydrogen bonds.
NMR relaxation data analysis
15N T1 and T2 relaxation data for each nucleus was fitted to a
monoexponential decay within CCPN Analysis and hetero-
nuclear NOE data was obtained as either (I 2 Io)/Io (g) or I/Io (g
2 1) for general or ModelFree analysis respectively. Reduced
spectral density and theoretical dipolar 15N T1, T2 calculations
(for correlation time estimation) were made using the equations
published by Kay and co-workers26 and include chemical
shift anisotropy contributions where appropriate. The simple
Lorentzian model for spectral density as used in Fig. 2, 3 and S9{
was taken to be J(v) = 2/5 [tm/(1 + v
2tm
2)]. Linear curve fitting
of spectral density data was achieved using KaleidaGraph
software. ModelFree 4.030,36–39 was used to provide order
parameters, internal motions and exchange broadening analysis.
Specific details regarding these analyses are given in the results
and discussion section of the text.
Determination of peptide integrin avb6 specificity by FACS
analysis
Cell lines A375P.Beta6.puro and A375P.puro10 were washed
with 20 mM Tris pH 7.5, 50 mM NaCl, 20 mM EDTA, 0.1%
BSA, 0.1% sodium azide and with 20 mM Tris pH 7.5, 50 mM
NaCl, 0.5 mM MgCl2, 1 mM CaCl2, 0.1% BSA, 0.1% sodium
azide (MGCA 0.1/0.1), then incubated with biotinylated
peptides. Cells were washed with MGCA 0.1/0.1 and bound
peptide detected with anti-biotin antibody (Jackson ImmunoRe-
search) followed by Alexa-488 anti-mouse (Molecular Probes).
Cells were analysed by flow cytometry (Beckton Dickinson
LSR-1 with CellQuest software) and signal normalised to
10D5 (anti-alphaVbeta6 monoclonal antibody) binding to
A375P.Beta6.puro.
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